Further Development of XenoPort (XNPT) '829 is Unwarranted, Cowen Says

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. SPY
8. CVS
9. UNH
10. VZ

Go back to Further Development of XenoPort (XNPT) '829 is Unwarranted, Cowen Says

XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis

September 15, 2015 6:30 AM EDT

Efficacy observed with both 800 mg once-daily and 400 mg twice-daily XP23829 dosing XP23829 safe and generally well-tolerated with low incidence of flushing similar to placebo Low incidence/severity of lymphopenia seen with XP23829 First clinical demonstration of efficacy of a MMF prodrug other than DMF

SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (Nasdaq: XNPT) announced today positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential... More